WO1998028255A1 - Preparation of gabapentin - Google Patents
Preparation of gabapentin Download PDFInfo
- Publication number
- WO1998028255A1 WO1998028255A1 PCT/US1997/023164 US9723164W WO9828255A1 WO 1998028255 A1 WO1998028255 A1 WO 1998028255A1 US 9723164 W US9723164 W US 9723164W WO 9828255 A1 WO9828255 A1 WO 9828255A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gabapentin
- solvent
- butanol
- hydrochloride
- methanol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- This invention relates to a new process for converting gabapentin hydrochloride salt to gabapentin via a novel polymorphic form of gabapentin.
- Gabapentin is 1- (aminomethyl) -1-cyclohexaneacetic acid, having the chemical structure:
- Gabapentin is used in the treatment of cerebral diseases such as epilepsy.
- the literature describes many ways of preparing gabapentin from a variety of starting materials.
- U.S. Patent 4,024,175 describes at least three methods of preparing gabapentin from cyclohexyl-1, 1-diacetic acid. Each of these methods results in the formation of gabapentin hydrochloride salt, which may be converted to 1- (aminomethyl) -1- cyclohexaneacetic acid by treatment with a basic ion exchanger and then crystallized from a solvent such as ethanol/ether .
- U.S. Patent 4,894,476 specifically discloses an improved method for converting the hydrochloride salt into the free amino acid. This involves pouring a deionized water solution of the salt over an ion exchange column, eluting with deionized water, producing a slurry from the eluate, adding an alcohol to the slurry, centrifuging and drying the slurry to obtain the free amino acid.
- gabapentin is crystalline and exhibits an X-ray diffraction pattern with peaks of 2-theta values at 7.8, 13.3, 15.0, 17.0, 20.4, 21.3, 23.1, 23.6, 25.7, 27.0 and 28.2 degrees.
- polymorph form "II" the commercially available polymorphic form of gabapentin is referred to as polymorph form "II".
- the present invention relates to an improved method for purifying gabapentin comprising converting gabapentin hydrochloride salt to gabapentin form II.
- the present invention avoids the disadvantages associated with prior art methods, by adding alternative steps and by proceeding via a novel polymorphic form of gabapentin.
- the present invention relates to a method of converting gabapentin hydrochloride salt to gabapentin form II, comprising reacting a solution of gabapentin hydrochloride with an additional amine in a first solvent to produce a novel polymorphic form as a precipitate, thereafter, converting the novel polymorphic form to form II by forming a suspension and/or a solution of the precipitate in methanol, and then recovering gabapentin form II.
- the present invention further relates to a novel polymorphic form of gabapentin designated as gabapentin form III.
- the polymorph may be identified by its unique X-ray diffraction pattern.
- a further aspect of the present invention relates to the novel polymorphic form of gabapentin that is of use as an intermediate in the preparation of polymorphic form II.
- Fig. 1 is an x-ray diffraction pattern of a sample of gabapentin hydrate.
- Fig. 2 is an x-ray diffraction pattern of gabapentin form II.
- Figs. 3a and 3b are x-ray diffraction pattern of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
- Fig. 4 is an FTIR (Fourier Transform Infra Red) spectrum of gabapentin hydrate.
- Fig. 5 is an FTIR spectrum of gabapentin form II.
- Fig. 6 is an FTIR spectrum of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
- the method of the present invention comprises:
- the gabapentin hydrochloride used as a starting material in the process of the present invention is substantially free of other inorganic salts such as sodium chloride and sodium bromide, that is, such impurities are only present in trace amounts.
- gabapentin hydrochloride containing inorganic salts may be used subject to the addition of a further step for removing the inorganic salts prior to mixing gabapentin hydrochloride with the additional amine.
- gabapentin hydrochloride containing inorganic salts may optionally be pre-treated to remove the inorganic salts by the steps of (a) dissolution in a solvent in which gabapentin hydrochloride is soluble, but the inorganic salts are not; (b) filtration of the inorganic salts and, optionally, (c) evaporating the solvent to recover gabapentin hydrochloride substantially free of inorganic salts.
- Appropriate solvents for the optional pre-treatment step include those selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, butanol, t-butanol, n-butanol, ethyleneglycolmonomethylether, benzylalcohol or dimethylacetamide.
- the pre-treatment solvent is identical to the first solvent.
- This pre-treatment solvent which is identified in Table 1 and in the claims as the "second solvent”, would be used prior to using the "first solvent", if, in fact, this optional pre-treament step is included in the process.
- the second step of the present invention comprises mixing a solution of the gabapentin hydrochloride in a solvent that contains an additional amine.
- the solvent may be any solvent in which the hydrochloride salt of the additional amine is soluble but in which gabapentin form III is insoluble, such that a precipitate of gabapentin form III is formed.
- Such solvents are preferably selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide.
- the precipitated gabapentin which may be separated by filtration, is characterized herein as a novel polymorphic form of gabapentin, possessing a crystalline structure characterized by peaks in the powder X ray diffraction pattern with 2-theta values at 6.11, 12.22, 17.00, 18.20, 19.94, 20.81, 24.54, and 25.11 degrees, all ⁇ 0.2 degrees.
- the x-ray diffraction pattern in the samples obtained appears to show a preferred orientation in which the peak at 6.11 degrees is larger than any other peak in the pattern, and the peaks at 12.22 and 24.54 degrees are larger than any of the remaining peaks in the pattern.
- This polymorph is referred to herein as gabapentin form III.
- Slurrying may be performed by suspending the precipitated gabapentin in methanol by mixing, stirring, and/or providing continuous agitation with some mechanical device so as to induce transformation into the gabapentin form II that is the commercially available polymorphic form of gabapentin. Gabapentin form II may then be filtered off and washed.
- the precipitated gabapentin may be crystallized from methanol with heating by reflux until dissolved, cooling, optionally seeding with gabapentin, followed by further cooling, and then collecting and drying the crystals of gabapentin form II. Second and multiple crops may be obtained from the concentrated mother liqueurs.
- Suitable amines for use in the present invention include triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine.
- the amine is tributylamine.
- the form II gabapentin obtained by the methods of the present invention may be crystallized using processes known in the art.
- Gabapentin hydrochloride containing inorganic salts NaCl, NaBr
- inorganic salts NaCl, NaBr
- Example 4 Variant A was dissolved in 150 ml isopropanol and mixed at 25°C. Active carbon (0.9 g) was added and the suspension mixed for a further 2 hours. The inorganic salts were removed by filtering. The filter cake was washed twice with 15 ml isopropanol and the washings were added to the gabapentin hydrochloride solution.
- the still humid filter cake from step 2 was suspended in 210 ml of methanol and the suspension was heated to reflux (65°C) . If dissolution was incomplete, additional methanol was added.
- the reactor content was cooled to 34°C at which temperature crystallization was induced by seeding with pure Form II gabapentin base (0.1 g) .
- the reactor content was cooled to 25°C and methanol was distilled by vacuum distillation. Approximately 160 ml of methanol was collected. Then the suspension was cooled to 0-10°C and maintained at this temperature for 2 hours .
- the crystalline gabapentin was separated by filtration from the suspension.
- the filter cake was washed with 20 ml methanol and then dried under vacuum at 35°C. 10.8 g of crystalline gabapentin form II (yield 72%) was thus obtained.
- Example 2-20 The method of Example 1 was followed using the slurrying technique of step C(l) and employing the amines and solvents shown in Table 1 below. The percent yields are of purified product except where marked with an asterisk (*) , where the yield was measured at the stage prior to the slurrying in methanol. Table 1. Summary of the first solvent, second solvent, amine and yield of examples 2-20.
- IPA isopropanol MEK methyl ethyl ketone ACN acetonitrile EGMME ethyleneglycol monomethylether BzOH benzyl alcohol TBA tributylamine MeOH methanol BzA benzylamine CH 2 C1 2 methylene chloride IPA Ac isopropylacetate THA trihexylamine DMC dimethylcarbonate TPA tripropylamine (t)-BuOH (tert) -butanol Et Ac ethyl acetate TEA triethylamine DMA dimethylacetamide DEA diethylamine
- the gabapentin form III was characterized by comparing the x- ray diffraction pattern and the FTIR absorption spectra of gabapentin form III with gabapentin form II and gabapentin hydrate.
- the x-ray powder diffraction patterns of Figures 1, 2, and 3a were obtained using a Philips x-ray powder diffractometer with the following parameters:
- Type of radiation copper K .
- Figure 3b was obtained using a Siemens B5100 with a presample (K ⁇ ! only) monochromator, step scan, Cu radiation, beam slits 0.3, receiving slit 0.05, standard Siemens rotating sample holder, start/stop/step angles in degrees were 4.0, 35, and 0.04, with a step duration of 15 seconds.
- Standard Siemens D- 5000 software was used.
- the diffractometer was calibrated with NIST large d-spacing standard. No theta-compensating slits were employed.
- Figs. 1-3 The x-ray spectra of gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 1-3, respectively.
- the main diffraction peaks that characterize each material are listed in Table 2.
- FTIR spectra for gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 4-6, respectively.
- the FTIR peaks are summarized in Table 3,
- the hydrate form typically exists as large crystals with undefined shapes.
- Form II typically exists as plate shaped crystals.
- Form III typically exists as small rhomboidal crystals.
- the melting point for gabapentin was not determined since gabapentin decomposes prior to melting.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
There is disclosed a method of converting gabapenting hydrochloride substantially free of inorganic salts to gabapenting form II. The method comprises the steps of: (1) obtaining gabapentin hydrochloride that is substantially free of inorganic salts; (2) mixing a solution of the gabapenting hydrochloride with an additional amine in a first solvent so as to obtain a precipitate comprising gabapenting; and then (3) recovering gabapentin form II from the precipitate. The precipitated gabapentin is a novel polymorphic form of gabapentin possessing a crystalline structure characterized by novel sets of peaks in the powder X-ray diffraction pattern and in the FTIR spectra. This newly disclosed polymorph of gabapentin is characterized herein as gabapentin form III. The recovery step may comprise, for example, one of two alternative methods, slurrying the gabapentin form II in methanol, and then filtering the suspension to obtain gabapentin form II, or solubilizing the gabapentin form III in methanol with heating by reflux, and then cooling the solution to obtain gabapentin form II by crystallization.
Description
PREPARATION OF GABAPENTIN
FIELD OF THE INVENTION
This invention relates to a new process for converting gabapentin hydrochloride salt to gabapentin via a novel polymorphic form of gabapentin.
BACKGROUND OF THE INVENTION
Gabapentin is 1- (aminomethyl) -1-cyclohexaneacetic acid, having the chemical structure:
Gabapentin is used in the treatment of cerebral diseases such as epilepsy. The literature describes many ways of preparing gabapentin from a variety of starting materials. U.S. Patent 4,024,175 describes at least three methods of preparing gabapentin from cyclohexyl-1, 1-diacetic acid. Each of these methods results in the formation of gabapentin hydrochloride salt, which may be converted to 1- (aminomethyl) -1- cyclohexaneacetic acid by treatment with a basic ion exchanger and then crystallized from a solvent such as ethanol/ether .
U.S. Patent 4,894,476 specifically discloses an improved method for converting the hydrochloride salt into the free amino acid. This involves pouring a deionized water solution of the salt over an ion exchange column, eluting with deionized water, producing a slurry from the eluate, adding an
alcohol to the slurry, centrifuging and drying the slurry to obtain the free amino acid.
Alternative methods for preparing gabapentin have been described that do not proceed via the hydrochloride or any other mineral acid salt. Such methods include those described in U.S. Patent Nos. 5,132,451, 5,095,148, 5,068,413. Each of these methods involve a cyanic intermediate which is hydrogenated under severe conditions to produce the free amino acid.
These methods are industrially impractical. Those methods comprising ion exchange columns require the use of large amounts of ion exchanger for lengthy periods of time to lower the level of chloride ions to the desired level. The alternative methods involve further more demanding steps.
Commercially available gabapentin is crystalline and exhibits an X-ray diffraction pattern with peaks of 2-theta values at 7.8, 13.3, 15.0, 17.0, 20.4, 21.3, 23.1, 23.6, 25.7, 27.0 and 28.2 degrees. Hereinafter, the commercially available polymorphic form of gabapentin is referred to as polymorph form "II".
SUMMARY OF THE INVENTION
The present invention relates to an improved method for purifying gabapentin comprising converting gabapentin hydrochloride salt to gabapentin form II. The present invention avoids the disadvantages associated with prior art methods, by adding alternative steps and by proceeding via a novel polymorphic form of gabapentin.
Accordingly, the present invention relates to a method of converting gabapentin hydrochloride salt to gabapentin form II, comprising reacting a solution of gabapentin hydrochloride
with an additional amine in a first solvent to produce a novel polymorphic form as a precipitate, thereafter, converting the novel polymorphic form to form II by forming a suspension and/or a solution of the precipitate in methanol, and then recovering gabapentin form II.
The present invention further relates to a novel polymorphic form of gabapentin designated as gabapentin form III. The polymorph may be identified by its unique X-ray diffraction pattern.
A further aspect of the present invention relates to the novel polymorphic form of gabapentin that is of use as an intermediate in the preparation of polymorphic form II.
Further objectives and advantages of the subject invention will be apparent to those skilled in the art from the detailed description of the disclosed invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an x-ray diffraction pattern of a sample of gabapentin hydrate.
Fig. 2 is an x-ray diffraction pattern of gabapentin form II.
Figs. 3a and 3b are x-ray diffraction pattern of gabapentin form III, possibly containing small amounts of gabapentin form II and/or gabapentin hydrate.
Fig. 4 is an FTIR (Fourier Transform Infra Red) spectrum of gabapentin hydrate.
Fig. 5 is an FTIR spectrum of gabapentin form II.
Fig. 6 is an FTIR spectrum of gabapentin form III, possibly
containing small amounts of gabapentin form II and/or gabapentin hydrate.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The subject invention will now be described in detail for specific preferred embodiments of the invention, it being understood that these embodiments are intended only as illustrative examples and the invention is not to be limited thereto.
The method of the present invention comprises:
(1) obtaining gabapentin hydrochloride that is substantially free of inorganic salts;
(2) mixing a solution of the gabapentin hydrochloride with an additional amine in a first solvent so as to obtain a precipitate comprising gabapentin; and then
(3) recovering gabapentin form II from the precipitate.
Preferably, the gabapentin hydrochloride used as a starting material in the process of the present invention is substantially free of other inorganic salts such as sodium chloride and sodium bromide, that is, such impurities are only present in trace amounts. Alternatively, gabapentin hydrochloride containing inorganic salts may be used subject to the addition of a further step for removing the inorganic salts prior to mixing gabapentin hydrochloride with the additional amine.
Thus, gabapentin hydrochloride containing inorganic salts may optionally be pre-treated to remove the inorganic salts by the steps of (a) dissolution in a solvent in which gabapentin hydrochloride is soluble, but the inorganic salts are not; (b) filtration of the inorganic salts and, optionally, (c) evaporating the solvent to recover gabapentin hydrochloride substantially free of inorganic salts. Appropriate solvents
for the optional pre-treatment step include those selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, butanol, t-butanol, n-butanol, ethyleneglycolmonomethylether, benzylalcohol or dimethylacetamide. Preferably the pre-treatment solvent is identical to the first solvent. This pre-treatment solvent, which is identified in Table 1 and in the claims as the "second solvent", would be used prior to using the "first solvent", if, in fact, this optional pre-treament step is included in the process.
The second step of the present invention comprises mixing a solution of the gabapentin hydrochloride in a solvent that contains an additional amine. The solvent may be any solvent in which the hydrochloride salt of the additional amine is soluble but in which gabapentin form III is insoluble, such that a precipitate of gabapentin form III is formed. Such solvents are preferably selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide. The precipitated gabapentin, which may be separated by filtration, is characterized herein as a novel polymorphic form of gabapentin, possessing a crystalline structure characterized by peaks in the powder X ray diffraction pattern with 2-theta values at 6.11, 12.22, 17.00, 18.20, 19.94, 20.81, 24.54, and 25.11 degrees, all ±0.2 degrees. The x-ray diffraction pattern in the samples obtained appears to show a preferred orientation in which the peak at 6.11 degrees is larger than any other peak in the pattern, and the peaks at 12.22 and 24.54 degrees are larger than any of the remaining peaks in the pattern. This polymorph is referred to herein as gabapentin form III.
Two representative embodiments of the third step of the present invention, recovery of gabapentin form II from the precipitate, are slurrying and crystallization. Slurrying may be performed by suspending the precipitated gabapentin in methanol by mixing, stirring, and/or providing continuous agitation with some mechanical device so as to induce transformation into the gabapentin form II that is the commercially available polymorphic form of gabapentin. Gabapentin form II may then be filtered off and washed.
Alternatively, the precipitated gabapentin may be crystallized from methanol with heating by reflux until dissolved, cooling, optionally seeding with gabapentin, followed by further cooling, and then collecting and drying the crystals of gabapentin form II. Second and multiple crops may be obtained from the concentrated mother liqueurs.
Suitable amines for use in the present invention include triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine. Preferably the amine is tributylamine.
The form II gabapentin obtained by the methods of the present invention may be crystallized using processes known in the art.
Certain specific representative embodiments of the invention are described in detail below, the materials, apparatus and process steps being understood as examples that are intended to be exemplary and illustrative only. In particular, the invention is not intended to be limited to the methods, materials, conditions, process parameters, apparatus and the like specifically recited herein.
EXAMPLES
1. Preparation of gabapentin from gabapentin hydrochloride
A. Removal of Inorganic Salts
Gabapentin hydrochloride containing inorganic salts (NaCl, NaBr) , which may be prepared, for example, as shown in U.S.
Pat. No. 4,024,175, Example 4, Variant A, was dissolved in 150 ml isopropanol and mixed at 25°C. Active carbon (0.9 g) was added and the suspension mixed for a further 2 hours. The inorganic salts were removed by filtering. The filter cake was washed twice with 15 ml isopropanol and the washings were added to the gabapentin hydrochloride solution.
B. Precipitation of Gabapentin Base; Formation of Gabapentin Form III The gabapentin hydrochloride solution of part A was concentrated to dryness in vacuum while ensuring that the temperature of the heating bath did not exceed 35°C. 210 ml ethylacetate and 16.5 ml tributylamine were added and the solution was mixed for 2 hours at 25°C. The gabapentin precipitate was then separated by filtration, the filter cake being washed with 20 ml ethylacetate and then 20 ml methanol. The filter cake contained gabapentin form III which when dried displayed a characteristic X-ray diffraction pattern with 2- theta values at 6.1, 12.2, 17.0, 17.7, 18.3, 20.0, 20.8, 24.6 and 25.5 degrees.
C. Alternative Methods for Conversion of Precipitated Gabapentin to Gabapentin Form II
(1) Slurrying
The still humid filter cake from step 2 was suspended in 52.5 ml methanol for about 14 hours at 25°C. Solid gabapentin was then separated from the suspension by filtration. The filter cake was washed with 20 ml methanol and then dried under vacuum at 35°C. 10.8 g crystalline gabapentin form II (yield 72%) was obtained.
(2 ) Crystallization
The still humid filter cake from step 2 was suspended in 210 ml of methanol and the suspension was heated to reflux (65°C) . If dissolution was incomplete, additional methanol was added.
After dissolution, the reactor content was cooled to 34°C at which temperature crystallization was induced by seeding with pure Form II gabapentin base (0.1 g) .
After maintaining the mixture at 34 °C for 60 minutes the reactor content was cooled to 25°C and methanol was distilled by vacuum distillation. Approximately 160 ml of methanol was collected. Then the suspension was cooled to 0-10°C and maintained at this temperature for 2 hours .
The crystalline gabapentin was separated by filtration from the suspension. The filter cake was washed with 20 ml methanol and then dried under vacuum at 35°C. 10.8 g of crystalline gabapentin form II (yield 72%) was thus obtained.
Examples 2-20 The method of Example 1 was followed using the slurrying technique of step C(l) and employing the amines and solvents shown in Table 1 below. The percent yields are of purified product except where marked with an asterisk (*) , where the yield was measured at the stage prior to the slurrying in methanol.
Table 1. Summary of the first solvent, second solvent, amine and yield of examples 2-20.
IPA isopropanol MEK methyl ethyl ketone ACN acetonitrile EGMME ethyleneglycol monomethylether BzOH benzyl alcohol TBA tributylamine MeOH methanol BzA benzylamine CH2C12 methylene chloride IPA Ac isopropylacetate THA trihexylamine DMC dimethylcarbonate TPA tripropylamine (t)-BuOH (tert) -butanol Et Ac ethyl acetate TEA triethylamine
DMA dimethylacetamide DEA diethylamine
The gabapentin form III was characterized by comparing the x- ray diffraction pattern and the FTIR absorption spectra of gabapentin form III with gabapentin form II and gabapentin hydrate. The x-ray powder diffraction patterns of Figures 1, 2, and 3a were obtained using a Philips x-ray powder diffractometer with the following parameters:
Goniometer model 1050/70, Cu-tube, Curved graphite monochromator .
Sample holder: Quartz monocrystal plate Settings :
X-Ray tube: KV-40 mA-28 Target-Cu Divergence slit-l° Receiving parallel slit-0.2 mm Scatter slit-l°
Scintillation detector: Voltage-832 Lower level-33.8% Window-34.5% Scan parameters:
Scanning speed: 2°/min Paper speed: 2cm/min Gain: 32
Calibration: External calibration with silicon fine powder
Type of radiation: copper K .
Figure 3b was obtained using a Siemens B5100 with a presample (Kα! only) monochromator, step scan, Cu radiation, beam slits 0.3, receiving slit 0.05, standard Siemens rotating sample
holder, start/stop/step angles in degrees were 4.0, 35, and 0.04, with a step duration of 15 seconds. Standard Siemens D- 5000 software was used. The diffractometer was calibrated with NIST large d-spacing standard. No theta-compensating slits were employed.
The x-ray spectra of gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 1-3, respectively. The main diffraction peaks that characterize each material are listed in Table 2.
Table 2. X-ray Diffraction peaks of gabapentin hydrate, gabapentin form II and gabapentin form III.
The FTIR spectra for gabapentin hydrate, gabapentin form II and gabapentin form III are shown in Figs. 4-6,
respectively. The FTIR peaks are summarized in Table 3,
Table 3. FTIR peaks of gabapentin hydrate, gabapentin form II and gabapentin form III.
Morphology of the three forms: 1. The hydrate form typically exists as large crystals with undefined shapes.
2. Form II typically exists as plate shaped crystals.
3. Form III typically exists as small rhomboidal crystals.
The melting point for gabapentin was not determined since gabapentin decomposes prior to melting.
Claims
1. A method of converting gabapentin hydrochloride to gabapentin form II comprising:
(1) dissolving gabapentin hydrochloride in a first solvent in which gabapentin is relatively insoluble; and
(2) adding an additional amine to the gabapentin hydrochloride solution so as to obtain a precipitate comprising gabapentin.
2. The method of claim 1, further comprising the step of recovering gabapentin form II from said precipitate.
3. The method of claim 2, the recovering step comprising slurrying or crystallizing said precipitate in methanol.
4. The method of claim 3, wherein said first solvent is selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide.
5. The method of claim 1 wherein said additional amine is selected from the group consisting of triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine.
6. The method of claim 5 wherein said additional amine is tributylamine .
7. The method of claim 1 wherein said first solvent is selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide.
8. The method of claim 7 wherein said first solvent is ethylacetate.
9. The method of claim 1 wherein said first solvent is one in which the hydrochloride salt of said additional amine is soluble .
10. The method of claim 1 further comprising pre-treating said gabapentin hydrochloride to remove inorganic salts, which pre-treatment comprises (a) dissolving gabapentin hydrochloride in a second solvent in which inorganic salts are insoluble, (b) filtering off the inorganic salts, and (c) recovering gabapentin hydrochloride from said second solvent.
11. The method of claim 10 wherein said second solvent is selected from the group consisting of methanol, ethanol, n- propanol, isopropanol, butanol, t-butanol, n-butanol, ethyleneglycolmonomethylether, benzylalcohol or dimethylacetamide .
12. The method of claim 11 wherein said second solvent is isopropanol .
13. The method of claim 1 or 10 wherein the precipitated gabapentin comprises gabapentin form III.
14. The method of claim 10 wherein the precipitated gabapentin comprises gabapentin form III, said second solvent is isopropanol, said first solvent is ethylacetate, and said additional amine is tributylamine.
15. The method of claim 14 wherein said precipitated gabapentin is slurried or crystallized from methanol to yield gabapentin form II.
16. Crystalline gabapentin form III characterized by powder X-ray diffraction peaks at 6.11+0.2, 12.2210.2, 17.00┬▒0.2, 17.6310.2, 18.20+0.2, 19.9410.2, 20.8110.2, 24.5410.2, 25.11+0.2, 28.9110.2, 30.2010.2, 30.7810.2, and 31.4610.2 degrees 2-theta.
17. Crystalline gabapentin form III characterized by powder X-ray diffraction peaks at 6.1110.2, 12.2210.2, 17.00+0.2, 17.63+0.2, 18.2010.2, 19.9410.2, 20.8110.2, 24.5410.2, 25.1110.2, 28.9110.2, 30.2010.2, 30.7810.2, and 31.4610.2 degrees 2-theta, wherein the size of the peaks is in the order 6.11 degrees > 12.22 and 24.54 > 17.00, 17.63, 18.20, 19.94, 20.81, 25.11, 28.91, 30.20, 30.78, and 31.46.
18. Crystalline gabapentin form III characterized by infra-red absorptions having peaks at 708, 760, 885, 926, 974, 1160, 1180, 1290, 1420, 1460, 1510, 1586, and 1664 cm"1.
19. Crystalline gabapentin form III produceable by a process comprising the steps of:
(a) dissolving gabapentin hydrochloride in a solvent selected from the group consisting of ethyl acetate, dimethylcarbonate, ethanol, butanol, t-butanol, n-butanol, methanol, acetonitrile, toluene, isopropylacetate, isopropanol, methylethylketone, acetone, ethyleneglycolmonomethylether, methylene chloride, chloroform, benzylalcohol or dimethylacetamide;
(b) adding an additional amine selected from the group consisting of triethylamine, tributylamine, tripropylamine, trihexylamine, diethylamine, ethanolamine and benzylamine; and
(c) drying the precipitated gabapentin.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97954134A EP0950044A4 (en) | 1996-12-24 | 1997-12-24 | Preparation of gabapentin |
| DE0000950044T DE97954134T1 (en) | 1996-12-24 | 1997-12-24 | PRODUCTION OF GABAPENTIN |
| US09/331,555 US6255526B1 (en) | 1996-12-24 | 1997-12-24 | Preparation of gabapentin |
| CA002275912A CA2275912A1 (en) | 1996-12-24 | 1997-12-24 | Preparation of gabapentin |
| AU57990/98A AU5799098A (en) | 1996-12-24 | 1997-12-24 | Preparation of gabapentin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11989096A IL119890A (en) | 1996-12-24 | 1996-12-24 | Gabapentin form iii and preparation of gabapentin form ii |
| IL119890 | 1996-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998028255A1 true WO1998028255A1 (en) | 1998-07-02 |
Family
ID=11069615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/023164 WO1998028255A1 (en) | 1996-12-24 | 1997-12-24 | Preparation of gabapentin |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0950044A4 (en) |
| AU (1) | AU5799098A (en) |
| CA (1) | CA2275912A1 (en) |
| DE (1) | DE97954134T1 (en) |
| ES (1) | ES2204362T1 (en) |
| IL (1) | IL119890A (en) |
| WO (1) | WO1998028255A1 (en) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2137137A1 (en) * | 1998-05-25 | 1999-12-01 | Medichem Sa | Non-hydrated gabapentine polymorph, production process and utilization for producing pharmaceutical grade gabapentine |
| WO2000058268A1 (en) * | 1999-03-26 | 2000-10-05 | Bioindustria Laboratorio Italiano Medicinali S.P.A. | A process for the preparation of gabapentin |
| WO2000064857A1 (en) * | 1999-04-26 | 2000-11-02 | Medichem S.A. | Process for producing gabapentine of pharmaceutical grade |
| US6294198B1 (en) | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
| WO2002044123A1 (en) * | 2000-12-01 | 2002-06-06 | Erregierre S.P.A. | A process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid |
| EP1294364A1 (en) * | 2000-06-16 | 2003-03-26 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin having ph within a controlled range |
| WO2003031391A1 (en) * | 2001-10-09 | 2003-04-17 | Warner-Lambert Company Llc | New anhydrous crystalline forms of gabapentin |
| EP1289364A4 (en) * | 2000-06-16 | 2003-08-06 | Teva Pharma | Stable gabapentin containing more than 2o ppm of chlorine ion |
| WO2003065982A2 (en) * | 2002-01-24 | 2003-08-14 | Xenoport, Inc. | Engineering absorption of therapeutic compounds via colonic transporters |
| EP1384473A1 (en) * | 2000-06-16 | 2004-01-28 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 20 ppm of chlorine ion |
| WO2004046085A1 (en) * | 2002-11-20 | 2004-06-03 | Hikal Ltd. | Process for the preparation of amino methyl cyclo alkane acetic acids |
| WO2004046084A1 (en) | 2002-11-18 | 2004-06-03 | Nicholas Piramal India Limited | Improved process for preparation of gabapentin |
| EP1430893A1 (en) * | 2000-06-16 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 20 ppm of chloride ion |
| WO2004093779A2 (en) * | 2003-04-21 | 2004-11-04 | Matrix Laboratories Ltd | Process for the preparation of gabapentin form-ii |
| WO2004093780A2 (en) * | 2003-04-21 | 2004-11-04 | Matrix Laboratories Ltd | Process for the preparation of gabapentin form-ii |
| WO2004106281A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Crystalline gabapentin |
| WO2004110981A1 (en) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | A process for the preparation of gabapentin form-ii |
| WO2004110342A2 (en) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | Novel polymorph of gabapentin and its conversion to gabapentin form-ii |
| WO2006002972A1 (en) * | 2004-07-05 | 2006-01-12 | Sandoz Ag | Process for the preparation of gabapentin |
| EP1619181A1 (en) * | 2004-07-20 | 2006-01-25 | Sandoz AG | Processes for the preparation of gabapentin |
| US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
| US7169812B2 (en) | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| US7393872B2 (en) | 1999-04-09 | 2008-07-01 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
| US7417166B2 (en) | 2004-03-25 | 2008-08-26 | Zach System S.P.A. | Process for the preparation of gabapentin |
| WO2008106217A1 (en) * | 2007-02-28 | 2008-09-04 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin by liquid-liquid extraction |
| WO2009015685A1 (en) | 2007-07-27 | 2009-02-05 | Medichem, S.A. | Method for preparing polymorph form ii of gabapentin |
| US8084447B2 (en) | 2001-09-03 | 2011-12-27 | Newron Pharmaceuticals S.P.A. | Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use |
| CN102363598A (en) * | 2011-11-25 | 2012-02-29 | 浙江精进药业有限公司 | Method for preparing high-purity gabapentin |
| US9481635B2 (en) | 2013-10-22 | 2016-11-01 | Zach System S.P.A. | Process for preparing gabapentin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4024175A (en) * | 1974-12-21 | 1977-05-17 | Warner-Lambert Company | Cyclic amino acids |
| US4960931A (en) * | 1988-05-02 | 1990-10-02 | Warner-Lambert Company | Gabapentin mohohydrate and a process for producing the same |
| US5068413A (en) * | 1989-08-25 | 1991-11-26 | Godecke Aktiengesellschaft | Process for the preparation of cyclic amino acids and intermediates useful in the process |
-
1996
- 1996-12-24 IL IL11989096A patent/IL119890A/en not_active IP Right Cessation
-
1997
- 1997-12-24 CA CA002275912A patent/CA2275912A1/en not_active Abandoned
- 1997-12-24 DE DE0000950044T patent/DE97954134T1/en active Pending
- 1997-12-24 EP EP97954134A patent/EP0950044A4/en not_active Withdrawn
- 1997-12-24 ES ES97954134T patent/ES2204362T1/en active Pending
- 1997-12-24 WO PCT/US1997/023164 patent/WO1998028255A1/en not_active Application Discontinuation
- 1997-12-24 AU AU57990/98A patent/AU5799098A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4024175A (en) * | 1974-12-21 | 1977-05-17 | Warner-Lambert Company | Cyclic amino acids |
| US4960931A (en) * | 1988-05-02 | 1990-10-02 | Warner-Lambert Company | Gabapentin mohohydrate and a process for producing the same |
| US5068413A (en) * | 1989-08-25 | 1991-11-26 | Godecke Aktiengesellschaft | Process for the preparation of cyclic amino acids and intermediates useful in the process |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP0950044A4 * |
Cited By (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999061408A1 (en) * | 1998-05-25 | 1999-12-02 | Medichem, S.A. | Non-hydrated gabapentine polymorph, production process and utilization for producing pharmaceutical grade gabapentine |
| ES2137137A1 (en) * | 1998-05-25 | 1999-12-01 | Medichem Sa | Non-hydrated gabapentine polymorph, production process and utilization for producing pharmaceutical grade gabapentine |
| US6576790B1 (en) | 1999-03-26 | 2003-06-10 | Bioindustria Laboratorio Italiano Medicinali S.P.A. | Process for the preparation of gabapentin |
| WO2000058268A1 (en) * | 1999-03-26 | 2000-10-05 | Bioindustria Laboratorio Italiano Medicinali S.P.A. | A process for the preparation of gabapentin |
| US7393872B2 (en) | 1999-04-09 | 2008-07-01 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
| WO2000064857A1 (en) * | 1999-04-26 | 2000-11-02 | Medichem S.A. | Process for producing gabapentine of pharmaceutical grade |
| ES2164527A1 (en) * | 1999-04-26 | 2002-02-16 | Medichen S A | Process for the preparation of anhydrous, pharmaceutical grade gabapentin |
| US6528682B1 (en) * | 1999-04-26 | 2003-03-04 | Medichem, S.A. | Process for producing gabapentin or pharmaceutical grade |
| US6294198B1 (en) | 1999-08-24 | 2001-09-25 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
| US6465012B2 (en) | 1999-08-24 | 2002-10-15 | Purepac Pharmaceutical Co. | Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same |
| EP1384473A1 (en) * | 2000-06-16 | 2004-01-28 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 20 ppm of chlorine ion |
| EP1294364A1 (en) * | 2000-06-16 | 2003-03-26 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin having ph within a controlled range |
| EP1289364A4 (en) * | 2000-06-16 | 2003-08-06 | Teva Pharma | Stable gabapentin containing more than 2o ppm of chlorine ion |
| AU2001266992B2 (en) * | 2000-06-16 | 2005-08-04 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin having ph within a controlled range |
| EP1294364A4 (en) * | 2000-06-16 | 2004-06-16 | Teva Pharma | Stable gabapentin having ph within a controlled range |
| EP1430893A1 (en) * | 2000-06-16 | 2004-06-23 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin containing more than 20 ppm of chloride ion |
| AU2001266992B8 (en) * | 2000-06-16 | 2005-12-01 | Teva Pharmaceutical Industries Ltd. | Stable gabapentin having pH within a controlled range |
| US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
| US7393974B2 (en) * | 2000-12-01 | 2008-07-01 | Erregierre S.P.A. | Process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid |
| WO2002044123A1 (en) * | 2000-12-01 | 2002-06-06 | Erregierre S.P.A. | A process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid |
| AU2002229575B2 (en) * | 2000-12-01 | 2006-12-07 | Erregierre S.P.A. | A process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid |
| US8710040B2 (en) | 2001-09-03 | 2014-04-29 | Newron Pharmaceuticals S.P.A. | Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use |
| US8084447B2 (en) | 2001-09-03 | 2011-12-27 | Newron Pharmaceuticals S.P.A. | Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use |
| US6800782B2 (en) | 2001-10-09 | 2004-10-05 | Warner-Lambert Co. | Anhydrous crystalline forms of gabapentin |
| WO2003031391A1 (en) * | 2001-10-09 | 2003-04-17 | Warner-Lambert Company Llc | New anhydrous crystalline forms of gabapentin |
| WO2003065982A3 (en) * | 2002-01-24 | 2005-12-08 | Xenoport Inc | Engineering absorption of therapeutic compounds via colonic transporters |
| WO2003065982A2 (en) * | 2002-01-24 | 2003-08-14 | Xenoport, Inc. | Engineering absorption of therapeutic compounds via colonic transporters |
| WO2004046084A1 (en) | 2002-11-18 | 2004-06-03 | Nicholas Piramal India Limited | Improved process for preparation of gabapentin |
| US7196216B2 (en) | 2002-11-18 | 2007-03-27 | Nicholas Piramal India Limited | Process for preparation of Gabapentin |
| US7635717B2 (en) | 2002-11-20 | 2009-12-22 | Hikal Limited | Process for the preparation of amino methyl cyclo alkane acetic acids |
| WO2004046085A1 (en) * | 2002-11-20 | 2004-06-03 | Hikal Ltd. | Process for the preparation of amino methyl cyclo alkane acetic acids |
| WO2004093780A3 (en) * | 2003-04-21 | 2004-12-16 | Matrix Lab Ltd | Process for the preparation of gabapentin form-ii |
| US7439387B2 (en) | 2003-04-21 | 2008-10-21 | Matrix Laboratories Ltd. | Process for the preparation of Gabapentin form-II |
| WO2004093779A2 (en) * | 2003-04-21 | 2004-11-04 | Matrix Laboratories Ltd | Process for the preparation of gabapentin form-ii |
| WO2004093780A2 (en) * | 2003-04-21 | 2004-11-04 | Matrix Laboratories Ltd | Process for the preparation of gabapentin form-ii |
| WO2004093779A3 (en) * | 2003-04-21 | 2004-12-16 | Matrix Lab Ltd | Process for the preparation of gabapentin form-ii |
| WO2004106281A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Crystalline gabapentin |
| WO2004110342A3 (en) * | 2003-06-12 | 2005-04-14 | Matrix Lab Ltd | Novel polymorph of gabapentin and its conversion to gabapentin form-ii |
| WO2004110342A2 (en) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | Novel polymorph of gabapentin and its conversion to gabapentin form-ii |
| WO2004110981A1 (en) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | A process for the preparation of gabapentin form-ii |
| US7169812B2 (en) | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| US7417166B2 (en) | 2004-03-25 | 2008-08-26 | Zach System S.P.A. | Process for the preparation of gabapentin |
| WO2006002972A1 (en) * | 2004-07-05 | 2006-01-12 | Sandoz Ag | Process for the preparation of gabapentin |
| EP1619181A1 (en) * | 2004-07-20 | 2006-01-25 | Sandoz AG | Processes for the preparation of gabapentin |
| US7098362B2 (en) | 2004-07-20 | 2006-08-29 | Sandoz Ag | Processes for the preparation of gabapentin |
| WO2008106217A1 (en) * | 2007-02-28 | 2008-09-04 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin by liquid-liquid extraction |
| WO2009015685A1 (en) | 2007-07-27 | 2009-02-05 | Medichem, S.A. | Method for preparing polymorph form ii of gabapentin |
| CN102363598A (en) * | 2011-11-25 | 2012-02-29 | 浙江精进药业有限公司 | Method for preparing high-purity gabapentin |
| US9481635B2 (en) | 2013-10-22 | 2016-11-01 | Zach System S.P.A. | Process for preparing gabapentin |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2204362T1 (en) | 2004-05-01 |
| EP0950044A1 (en) | 1999-10-20 |
| EP0950044A4 (en) | 2003-03-26 |
| DE97954134T1 (en) | 2004-04-15 |
| IL119890A0 (en) | 1997-03-18 |
| CA2275912A1 (en) | 1998-07-02 |
| AU5799098A (en) | 1998-07-17 |
| IL119890A (en) | 2002-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6255526B1 (en) | Preparation of gabapentin | |
| WO1998028255A1 (en) | Preparation of gabapentin | |
| JPS585904B2 (en) | Method for producing guanidine and its salts | |
| CN109836424B (en) | Method for preparing caffeine by methylation of environment-friendly theophylline sodium salt | |
| RU2586117C2 (en) | Crystallisation of epirubicin hydrochloride | |
| JP3182946B2 (en) | Method for producing N- (α-alkoxyethyl) formamide | |
| WO2008096373A2 (en) | Process for synthesizing highly pure nateglinide polymorphs | |
| EP0611369A1 (en) | Process for preparing (s) (+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione) | |
| JP3318992B2 (en) | Method for producing N- (α-alkoxyethyl) formamide | |
| JP2988019B2 (en) | Method for producing sodium N-alkylaminoethanesulfonate | |
| CN109689620B (en) | Method for resolving baclofen salt | |
| KR101287425B1 (en) | Preparation of crystalline form II of glyceryl phosphoryl choline | |
| KR101287422B1 (en) | Crystalline form I of glyceryl phosphoryl choline | |
| JP3042122B2 (en) | Method for producing N-cyanoacetamidine derivative | |
| JP3848714B2 (en) | Process for producing ethylenediamine-N, N'-disuccinic acid and its ferric complex salt | |
| KR101287423B1 (en) | Crystalline form II of glyceryl phosphoryl choline | |
| CN113087680A (en) | DOTA crystal form and preparation method thereof | |
| JP2942380B2 (en) | Method for purifying methacrylamide | |
| CN106432197B (en) | Ledipasvir intermediate mono-p-toluenesulfonate, crystal form and preparation method thereof | |
| JPH10316646A (en) | Production of high-purity crystalline o-methyliso urea acetate and crystalline o-methylisourea acetate obtained by the same | |
| JPH1180099A (en) | Preparation of (1r,2r)-1-amino-2-indanol-(r,r)-tartrate methanol solvate | |
| WO2006090208A1 (en) | Process and methods for the preparation of gabapentin and its intermediates | |
| CN117164464A (en) | Crystal form of trientine hydrate and preparation method thereof | |
| CN117186163A (en) | Sucralose-6-acetate purification process | |
| JPS6327477A (en) | Production of oxiracetam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2275912 Country of ref document: CA Ref country code: CA Ref document number: 2275912 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09331555 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1997954134 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997954134 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997954134 Country of ref document: EP |